Every 10-Q that LB Pharmaceuticals Inc (LBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc. reported significantly higher operating spending as it advances its lead neuromedicine candidate LB‑102 through late-stage trials. For the six months ended June 30, 2026, the company recorded a net loss of $70.7 million versus $10.2 million a year earlier, driven mainly by research and development expenses of $58.8 million and general and administrative expenses of $17.2 million.
Cash, cash equivalents and marketable securities totaled $327.8 million at June 30, 2026, plus a subsequent July 2026 private placement that raised $150.0 million in gross proceeds. Management states these resources, including the July financing, are expected to fund operations beyond the second quarter of 2029 as LB‑102 progresses through Phase 3 in schizophrenia, Phase 2 in bipolar depression, and additional planned indications.
LB Pharmaceuticals Inc. reported a larger net loss as it ramped up late-stage development of its lead drug LB-102 while significantly strengthening its balance sheet. For the quarter ended March 31, 2026, net loss widened to $19.1 million, driven by higher research and development expenses of $14.6 million and general and administrative costs of $7.5 million.
Cash, cash equivalents and marketable securities rose to $365.6 million, helped by a $100.0 million February 2026 private placement of common stock and pre-funded warrants. Operating cash burn was $23.3 million in the quarter. The company expects its current capital to fund operations into the second quarter of 2029 as it runs a Phase 3 schizophrenia trial (NOVA-2), a Phase 2 bipolar depression trial (ILLUMINATE-1), an open-label safety study (NOVA-3), and prepares a Phase 2 adjunctive major depressive disorder trial.
LB Pharmaceuticals (LBRX) reported Q3 2025 results highlighted by its September IPO and a much stronger balance sheet. The company posted a Q3 net loss of $3.6 million, a significant improvement from $14.2 million a year ago, as research and development ($2.4 million) and general and administrative ($2.8 million) expenses were lower.
The IPO closed on September 12, issuing 21,850,000 shares at $15.00 for $327.8 million gross and $302.3 million net. All preferred shares converted into 3,191,334 common shares immediately prior to closing, following a 1‑for‑27.8874 reverse stock split on September 8. As of September 30, cash and cash equivalents were $269.7 million and marketable securities were $44.7 million, bringing cash and securities to $314.5 million. Management states these resources fund operations for at least twelve months from issuance of the statements.
Total assets were $320.7 million against liabilities of $10.5 million, with stockholders’ equity of $310.2 million. The derivative warrant liability decreased to $0.9 million. 25,299,102 common shares were outstanding as of November 6, 2025. The company’s lead candidate, LB‑102, is described as Phase 3‑ready for acute schizophrenia.